{"id":"W4396587819","doi":"10.1158/1538-7445.sabcs23-po3-16-12","title":"Abstract PO3-16-12: European real-world experience of patients with HER2+ advanced/metastatic breast cancer accessing trastuzumab deruxtecan through a named patient program: first interim analysis of EUROPA T-DXd","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Trastuzumab; Medicine; Metastatic breast cancer; Interim; Oncology; Breast cancer; Cancer; Interim analysis; Internal medicine; Clinical trial; Political science","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01124686,0.0005920697,0.0009928402,0.000385729,0.0003664129,0.002017367,0.0007642796,0.0009310498,0.00291407],"category_scores_gemma":[0.01018023,0.0003415826,0.00220959,0.0008960548,0.0006202142,0.001074003,0.001582979,0.001182168,0.000702714],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001349979,"about_ca_system_score_gemma":0.001768274,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002787073,"about_ca_topic_score_gemma":0.001562557,"domain_scores_codex":[0.9947607,0.00329339,0.0003308559,0.0006188168,0.0004839384,0.0005122969],"domain_scores_gemma":[0.9893411,0.003528019,0.003485713,0.001465642,0.0006835276,0.001496035],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2142783,0.00843188,0.7145321,0.0004649797,0.003523648,0.0006009298,0.0007715007,0.005139523,0.001506832,0.0004400647,0.00562903,0.04468126],"study_design_scores_gemma":[0.02737147,0.05349704,0.8949284,0.0002283769,0.002808316,0.00101832,0.0008821131,0.005804502,0.002399011,0.0004181334,0.01051626,0.0001281485],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941624,0.0004267391,0.0005669527,0.0001422631,0.00001451784,0.0002337056,0.003529566,0.00002211067,0.0009017377],"genre_scores_gemma":[0.984658,0.0002052598,0.0008122057,0.0003139929,0.00003756263,0.0004978364,0.01237244,0.00003682515,0.00106582],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01124686,"threshold_uncertainty_score":0.05947977,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09008420133693715,"score_gpt":0.4725778209887704,"score_spread":0.3824936196518333,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}